The U.S. Food and Drug Administration (FDA) granted a supplemental approval for Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) for efficacy on June 18, 2024. This regulatory action, identified as BLA 761106 S-10, indicates an update to the drug's approved uses or characteristics based on new data supporting its effectiveness.
Background
Herceptin Hylecta is a fixed-dose coformulation of trastuzumab, a humanized monoclonal antibody, and hyaluronidase-oysk, an enzyme that facilitates the subcutaneous dispersion and absorption of co-administered drugs. This combination allows for subcutaneous administration of trastuzumab, which is typically administered intravenously. The drug is sponsored by Genentech Inc. and the recent supplemental approval specifically pertains to its efficacy, further solidifying its role in treatment.
What this means
A supplemental approval for efficacy indicates that the FDA has reviewed new or additional clinical data demonstrating the effectiveness of Herceptin Hylecta (trastuzumab and hyaluronidase-oysk). Such approvals typically result in an updated drug label, which may include a new or expanded indication, a new patient population, or revised dosing and administration information that enhances its clinical utility. For healthcare professionals, this means access to the latest evidence-based information regarding the drug's benefits, potentially offering new or refined treatment strategies for patients who could benefit from Herceptin Hylecta. This type of approval reinforces the drug's therapeutic value and provides updated guidance for its appropriate use in clinical practice.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA). The approval for BLA 761106 S-10, relating to Herceptin Hylecta (trastuzumab and hyaluronidase-oysk), was recorded on June 18, 2024, and is publicly accessible on the accessdata.fda.gov website, which serves as the official database for FDA regulatory actions.